

## Publications of the International Breast Cancer Study Group

### Trial VI

53. Hürny Ch, Bernhard J, Gelber RD, Coates A, Castiglione M, Isley M, Dreher D, Peterson J, Goldhirsch A, Senn JH for the International Breast Cancer Study Group: Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. *Eur J Cancer* 28:118-124, 1992. (Trials VI-VII)
68. Hürny C, Bernhard J, Coates A, Castiglione M, Peterson H, Gelber RD, Rudenstam C-M, Goldhirsch A, Senn H-J for the International Breast Cancer Study Group: Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient estimation. *Ann Oncol* 5:65-74, 1994. (Trials VI-VII)
79. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ, for the International Breast Cancer Study Group (IBCSG). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. *Med Care* 34:234-248, 1996. (Trials VI-VII)
80. Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M for the International Breast Cancer Study Group: Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. *Int J Rad Onc Biol Phys* 35:649-659, 1996. (Trials VI-VII)
82. Bernhard J, Hürny C, Coates A, Gelber R: Applying Quality of Life Principles in International Cancer Clinical Trials. *Int Clin Trials* 72:693-705, 1996. (Trials VI-VII)
83. The International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. *J Clin Oncol* 14:1885-1894, 1996. (Trial VI)
84. Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Rudenstam C-M, Lindtner J, Collins J, Crivellari D, Simoncini E, Forbes JF, Senn H-J, Goldhirsch A for the International Breast Cancer Study Group (IBCSG): Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. *Lancet* 347:1279-1284, 1996. (Trials VI-VII)
87. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn H-J, Rudenstam C-M for the International Breast Cancer Study Group (IBCSG). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. *Ann Oncol* 8:825-835, 1997. (Trials VI-VII)
88. Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Thürlimann B, Rudenstam C-M, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Simoncini E, Fey M, Pagani O, Price K, Senn H-J and other members of the IBCSG. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Ann Oncol* 8:751-756, 1997. (Trial VI)
96. Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, Gelber RD, Castiglione-Gertsch M, Hürny C for the International Breast Cancer Study Group. Quality of life assessment in international breast cancer study group (IBCSG) trials: practical issues and factors associated with missing data. *Stat Med* 17:587-601, 1998. (Trials VI-VII)
100. Bernhard J, Hürny Ch, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thürlimann B, Forbes JF, Goldhirsch A, Senn H-J, Rudenstam C-M, for the IBCSG. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. *Br J Cancer* 78:686-693, 1998. (Trials VI-VII)
102. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C.-M, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn H.J. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Eur J Cancer* 34:632-640, 1998. (Trial VI)
105. Colleoni M, Price K, Castiglione-Gertsch M, Gelber R, Coates A, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, fluorouracil (CMF regimen). *Lancet* 354:130-131, 1999. (Trials I-VII)
107. Coates AS, Hürny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, for the IBCSG. Quality of life scores predict outcome in metastatic but not in early breast cancer. *J Clin Oncol*, 18:

3768-3774, 2000. (Trials VI-VII)

108. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortés-Funes H, Veronesi A, Fey M, Rudenstam C-M, for the International (Ludwig) Breast Cancer Study Group. Identifying breast cancer patients at high risk for bone metastases. *J Clin Oncol*, 18: 3925-3935, 2000. (Trials I-VII)

112. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortés-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? *Lancet*, 355: 1869-1874, 2000. (Trials I-VI)

119. Goldhirsch A, Gelber RD, Yothers G, Gray, RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. *J Natl Cancer Inst Monogr*, No. 30:44-51, 2001. (Trials I-VI)

124. Bernhard J, Sullivan M, Hürny C, Coates AS, Rudenstam C-M. Clinical relevance of single item quality of life indicators in cancer clinical trials. *Br J Cancer* 84:1156 – 1165, 2001. (Trials VI-VII)

125. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD, for the International Breast Cancer Study Group (IBCSG). Effect of pregnancy on overall survival following the diagnosis of early stage breast cancer. *J Clin Oncol*, 19:1671-1675, 2001. (Trials V and VI)

126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)

130. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam CM, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A for the International Breast Cancer Study Group and the German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). *Br J Cancer* 86:1705-1714, 2002. (Trial VI)

134. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, and Collins J for the IBCSG. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I Through VII. *J Clin Oncol* 21:1205-1213, 2003. (Trials I-VII)

145. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Erzen D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, on behalf of the IBCSG. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15: 875-884, 2004. (Trials I-VII)

146. Sabbioni MEE, Bernhard J, Siegrist H-P, Schmitz S-FH, Castiglione-Gertsch M, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C for the SAKK. Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? *Breast Cancer Research and Treatment* 87: 75-86, 2004. (VI, VII, VIII, IX, 13-93, 14-93)

151. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the International Breast Cancer Study Group experience. *J Clin Oncol* 23:1390-1400, 2005. (Trials I-VII, IX) (Journal impact factor 9.8)

155. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687-1717, 2005. (Trials II, III, VI, VII, IX, 11-93) (Journal impact factor 21.7)

158. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A for the International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. *Lancet* 366:1108-1110, 2005. (Trials I, II, V, VI) (Journal impact factor 21.7)

159. Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A, for the IBCSG. Prognostic value of extracapsular tumor spread for locoregional

control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: Long-term observations from International Breast Cancer Study Group Trial VI. *J Clin Oncol* 23:7089-7097, 2005. (Trial VI) (Journal impact factor 9.8)

169. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A for the IBCSG. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Ann Oncol* 17:935-944, 2006. (Trials I-IX) (Journal impact factor 4.3).

184. Karlsson P, Cole BF, Price, KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *J Clin Oncol* 25:2019-2026, 2007. (Trials I-IX) (Journal impact factor 11.8)

190. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI, *Eur J Cancer* 43:1646-1653, 2007. (Trials V and VI) (Journal impact factor 3.7)

209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).

212. Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA, for the International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Ann Oncol* 19:1393-1401, 2008. (Trial VI) (Journal impact factor 4.9).

252. Karlsson P, Cole BF, Colleoni M, Roncadin M, Chua B, Murray E, Price KN, Castiglione-Gertsch, Goldhirsch A, Gruber G for the IBCSG. Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy. *Int J Rad Onc Biol Phys* 80:398-402, 2011. (Trials VI, VII, IX) (Journal impact factor 4.59).